2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1485

Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Abstract Number: 1486

Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Abstract Number: 1487

Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Abstract Number: 1488

Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Abstract Number: 1489

“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Abstract Number: 1490

Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control
Abstract Number: 1491

Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
Abstract Number: 1492

Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Abstract Number: 1493

Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Abstract Number: 1494

Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Abstract Number: 1495

Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Abstract Number: 1496

Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
Abstract Number: 1497

PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
Abstract Number: 1498

Serum MMP-3 More Than 155ng/Ml at Baseline Predicts One-Year Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 1499

Elevated Serum MMP-3 in Remission Predicts Relapsed in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].